ANTHEM: Q2FY27 accelerated on CRDMO growth, with EBITDA margin at a record 50.6%

What happened

Anthem reported that Q2FY27 revenue and margins accelerated, led by its CRDMO business, with EBITDA margin reaching 50.6%. First-half revenue fell year on year, while EBITDA and PAT rose, and net cash was ₹15,380 Mn at September 30, 2026.

Confirmed

Global impact / market context

A record EBITDA margin, which means profit as a share of sales before interest, taxes, depreciation and amortization, shows Anthem kept more profit from each sale even as first-half revenue declined. That mix shift toward higher-value CRDMO work supports earnings and cash generation for investors.

Analyst inference

Anthem is a contract research and manufacturing company, so CRDMO growth signals demand from drug developers outsourcing work. Falling first-half revenue alongside rising profit and cash suggests a shift toward higher-margin services rather than volume growth, a pattern investors weigh against peers.

Analyst inference

What to watch

1. Track whether the record 50.6% EBITDA margin holds in coming quarters, since first-half revenue already declined year on year and margin gains may not repeat. Confirmed
2. Watch for company disclosure on whether CRDMO capacity additions are planned, and whether that capital spending is funded from the reported net cash rather than new borrowing. Proposed
3. Monitor whether higher-margin CRDMO work keeps lifting profit if revenue stays weak; a margin-led earnings pattern can fade once cost savings and service mix stop helping. Analyst inference

Evidence

• Original source link unavailable